Continuous Nebulized Albuterol Versus Nebulized Albuterol and Ipratropium Bromide

Street Science


 
 

Keith Wesley | | Wednesday, June 27, 2007


Review of: Salo D, Tuel M, Lavery R, et al: "A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 MG) for the treatment of acute asthma." The Journal of Emergency Medicine. 31(4):371-376, 2006

The Science

The authors of this study attempted to determine if adding ipratropium bromide (Atrovent) to albuterol was superior in effect to albuterol alone, when both are given as a continuous non-stop nebulization for acute asthma attacks. Patients were randomized into two groups. During a two hour period, one group got 15 mg of albuterol, while the second group got 15 mg of albuterol and 2 mg of Atrovent nebulized. The primary outcome measure was peak flows measured at one and two hours.

Both the control group (albuterol alone) and the study group (albuterol plus Atrovent) had similar initial respiratory rates and peak flows. They all received oral prednisone at the outset.

At the one and two hour mark, they found no significant difference in peak flows of either group. Therefore, they concluded that adding Atrovent to a continuous neb is without significant benefit.

The Street

Several studies have shown added benefit of providing continuous nebs for bronchospasm, compared to repeated intermittent nebs. Most of the benefit is probably from less interruption in providing care that occurs when you provide a single neb, than when you evaluate a patient, find them still wheezing and then have to mix up another neb.

Atrovent has been proposed as an adjunct to the treatment of bronchospasm through its blunting of the parasympathetic nervous system, which allows the sympathetic beta agonist effect to be more effective. However, some studies indicate that the value of Atrovent is seen more often in older patients and those with COPD, because the parasympathetic nervous system predominates.

In this study, which was limited to asthma, the median age of the patients in both the study and control group was less than 40-years-old. Also, 95% of the patients were African American, which raises the question of racial differences in the pathophysiology for asthma.

While this study did not show a significant improvement, it may be that studies need to examine its use in older patients.




Connect: Have a thought or feedback about this? Add your comment now
Related Topics: Airway and Respiratory, Medical Emergencies, Research

What's Your Take? Comment Now ...

Featured Careers & Jobs in EMS

 

 

Get JEMS in Your Inbox

 

Fire EMS Blogs


Blogger Browser

Today's Featured Posts

 

EMS Airway Clinic

Innovation & Progress

Follow in the footsteps of these inspirational leaders of EMS.
More >

Multimedia Thumb

Abilene Loses Helicopter Service

Native Air leaves city with only one air helicopter service.
Watch It >


Multimedia Thumb

D.C. Fire Chief Proposes another Controversial Ambulance Plan

Staffing change will leave immediate neighborhood without fire apparatus.
Watch It >


Multimedia Thumb

FDIC 2014 CHAT: MIKE MCEVOY AND A.J. HEIGHTMAN

Mike McEvoy and A.J. Heightman discuss some new EMS technology at FDIC 2014.
Watch It >


Multimedia Thumb

D.C. Lieutenant in Patient Death May Go Unpunished

Family upset that officer in charge may retire without any discipline.
Watch It >


Multimedia Thumb

LMA MAD Nasal™

Needle-free intranasal drug delivery.
Watch It >


Multimedia Thumb

Braun Ambulances' EZ Door Forward

Helps to create a safer ambulance module.
Watch It >


Multimedia Thumb

The AmbuBus®, Bus Stretcher Conversion Kit - EMS Today 2013

AmbuBus®, Bus Stretcher all-hazards preparedness & response tool
Watch It >


More Product Videos >